Rapport Therapeutics (RAPP) Financials

Rapport Therapeutics is still very much a pre-commercial biotech story, and the latest quarter shows the classic tradeoff for investors in the sector: no product revenue yet, heavy research spending, but a very strong cash position that gives the company a long runway.

In Q1 2026, Rapport reported $20.0 million in revenue, but that was not enough to cover its operating costs. The company posted a net loss of $19.9 million, though that was an improvement from the $33.8 million loss in Q4 2025. Operating expenses also came down sequentially, which suggests some moderation in spending after a very expensive prior quarter.

The balance sheet remains the biggest positive. As of March 31, 2026, Rapport held about $476.9 million in cash, cash equivalents, short-term investments, and restricted cash. That is a substantial cash cushion for a company at this stage and should support ongoing clinical development without an immediate financing need.

At the same time, operating cash flow was still negative, with Q1 2026 operating cash burn of $13.1 million. The company also continues to spend heavily on R&D, which is expected for a clinical-stage biotech but means losses are likely to persist until programs mature or the company generates more meaningful revenue.

• Strong liquidity: cash, equivalents, and short-term investments totaled about $476.9 million at the end of Q1 2026.
• Improving quarterly loss: net loss narrowed to $19.9 million in Q1 2026 from $33.8 million in Q4 2025.
• Operating expenses declined sequentially: total operating expenses fell to $44.2 million from $38.5 million in Q4 2025, while Q1 2026 still showed disciplined spending relative to prior growth in losses.
• Interest income helps offset losses: the company generated $4.4 million in interest and investment income in Q1 2026.
• Cash balance increased sharply from year-end: cash and equivalents rose to $78.1 million from $25.4 million in Q4 2025, helped by investment activity and financing inflows.
• Stockholders’ equity remains large: total equity was about $471.5 million in Q1 2026.
• No product revenue trend to judge yet: quarterly revenue remains limited and does not yet show a durable commercial business model.
• Still unprofitable: Rapport posted a $19.9 million net loss in Q1 2026.
• Negative operating cash flow: operations used $13.1 million in cash during Q1 2026.
• Heavy R&D spending continues: research and development expense was $32.7 million in Q1 2026, which will keep pressure on profitability until programs advance.

Looking at the broader trend, Rapport’s quarterly losses have generally remained substantial over the past year, but the company’s spending pattern appears to have become more manageable than the peak seen in late 2025. The key takeaway for retail investors is that Rapport has time—thanks to its cash reserve—but the investment case will depend on clinical progress and whether the company can eventually convert its pipeline into durable value.